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Abstract 
 
Aims: This paper provides a concise review of the efficacy, effectiveness and affordability of 
healthcare interventions to promote and assist tobacco cessation, in order to inform national 
guideline development and assist countries in planning their provision of tobacco cessation support. 
 
Methods: Cochrane reviews of randomised controlled trials (RCTs) of major healthcare tobacco 
cessation interventions were used to derive efficacy estimates in terms of percentage-point increases 
relative to comparison conditions in 6-12 month continuous abstinence rates. This was combined 
with analysis and evidence from ‘real world’ studies to form a judgement on the likely effectiveness 
of each intervention in different settings. The affordability of each intervention was assessed for 
exemplar countries in each World Bank income category (low, lower middle, upper middle, high). 
Based on WHO criteria, an intervention was judged as affordable for a given income category if the 
estimated extra cost of saving a life-year was less than or equal to the per-capita Gross Domestic 
Product for that category of country. 
 
Results: Brief advice from a healthcare worker given opportunistically to smokers attending 
healthcare services can promote smoking cessation and is affordable for countries in all World Bank 
income categories (i.e., globally). Proactive telephone support, automated text messaging 
programmes, and printed self-help materials can assist smokers wanting help with a quit attempt and 
are affordable globally. Multi-session, face-to-face behavioural support can increase quit success for 
cigarettes and smokeless tobacco and is affordable in middle and high income countries. Nicotine 
replacement therapy, bupropion, nortriptyline, varenicline and cytisine can all aid quitting smoking 
when given with at least some behavioural support; of these cytisine and nortriptyline are affordable 
globally. 
 
Conclusions: Brief advice from a healthcare worker, telephone helplines, automated text messaging, 
printed self-help materials, cytisine and nortriptyline are globally affordable healthcare interventions 
to promote and assist smoking cessation. Evidence on smokeless tobacco cessation suggests that 
face-to-face behavioural support and varenicline can promote cessation.  
This article is protected by copyright. All rights reserved. 
Introduction 
 
Stopping smoking improves life-expectancy and reduces the risk of chronic disease. The earlier the 
age of stopping, the greater the benefit; studies in the UK and US estimate that stopping in young 
adulthood recovers an average of 10 years of life (1, 2). The health risks from other forms of tobacco 
use are mostly lower (in the case of Swedish-type snus, much lower) than from smoking but 
reducing prevalence of tobacco use in general is an important public health goal (3). Interventions 
that promote and assist smoking cessation are among the most cost-effective life-preserving 
interventions available in high income countries; interventions that can help as few as one per cent of 
smokers to stop for at least 6 months can be highly cost effective ways of saving lives (4). 
Interventions to promote and assist smoking cessation include mass media campaigns, advertising 
bans, fiscal measures and legislation to ban smoking in indoor public areas (5) as well as ‘healthcare 
interventions’, i.e., interventions typically delivered or made available to individuals through a 
country’s healthcare system (6).  
 
Healthcare interventions to promote and support smoking cessation have a strong evidence base and 
are available in many countries. These interventions include brief advice and behavioural support 
from healthcare workers and a range of medications, including nicotine replacement therapy, 
varenicline, bupropion, nortriptyline and cytisine (7-10). These interventions may be paid for 
directly by individual smokers, health insurance companies or the state. There is far less research on 
interventions to support cessation from other forms of tobacco use but such evidence does exist. 
 
The WHO Framework Convention on Tobacco Control (FCTC) (11) is a UN health treaty that sets 
out a range of measures that countries should take to reduce tobacco use. By October 2014 there 
were 179 Parties to the Treaty, making it one of the most widely adopted of all UN treaties. Article 
14 of the Treaty obliges Parties to the treaty to "develop and disseminate ... guidelines based on 
scientific evidence ... and take effective measures to promote cessation ... and treatment of tobacco 
dependence." In November 2010 the fourth Conference of the Parties to the treaty adopted 
guidelines for the implementation of Article 14 which set out in more detail the steps Parties should 
take to develop tobacco cessation support systems (12). These guidelines recommend that Parties 
strengthen or create sustainable infrastructure to motivate quit attempts and ensure wide access to 
cessation support. However a recent global survey shows that in many countries relatively little 
progress has been made on this (13). 
 
This paper aims to assist the process of implementing Article 14 of the FCTC by assessing the 
efficacy, effectiveness and affordability of the major healthcare interventions to promote and assist 
tobacco cessation, in most cases relating to smoking (14). It provides a concise summary of the 
evidence which, with an accompanying affordability calculator spreadsheet, can be used in guideline 
development, and in selecting cessation interventions appropriate to a country’s current situation and 
resources. Countries would otherwise need to undertake such a review themselves, a process that can 
be time-consuming and costly, especially for low and middle income countries (15).   
 
We use Cochrane reviews of tobacco cessation interventions to obtain efficacy estimates in terms of 
the percentage of tobacco users in RCTs helped to stop by those interventions. We then review 
additional studies that may help form a judgement about the real world effectiveness of the 
interventions, and contextual and implementation factors that may enhance or reduce this 
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effectiveness. Then we estimate the incremental cost-effectiveness ratios (ICERs) for the effective 
interventions for countries in different World Bank income categories. ICERs give the incremental 
cost incurred for an incremental health outcome, usually expressed as cost per life year gained or 
cost per quality-adjusted life year gained. Because ICERs are the ratio of the change in costs to 
incremental benefits of an intervention, they are good measures to compare different interventions 
used in tobacco cessation and across countries. These ICERs can then be used to assess the 
affordability of the interventions globally taking account of income levels in relevant countries.  
 
The paper and the affordability calculator have undergone extensive review, user testing and revision 
prior to submission as a published article, with an advisory group of key stakeholders in low and 
middle income countries, to help ensure that they meet their needs. The members of the advisory 
panel are listed in Box 1.  
 
Box 1: International advisory panel 
 
Lekan Ayo-Yusuf, Dean & Director, University of Limpopo MEDUNSA Campus, South Africa; 
Beatriz Champagne, Executive Director, InterAmerican Heart Foundation, Buenos Aires, 
Argentina; Elma Correa-Acevedo, Pneumologist and Tobacco Clinic Coordinator, Instituto 
Nacional de Cancerología, México City, México City; Thomas Glynn, Consulting Professor, 
Stanford Prevention Research Center, School of Medicine, Stanford University; USA; Feras 
Hawari, Director, Cancer Control Office and Chief, Section of Pulmonary and Critical Care, King 
Hussein Cancer Centre, Amman, Jordan; Hom Lal Shresha, Honorary Research Fellow, Non-
Smokers' Rights Association of Nepal, Kathmandu, Nepal; Vimla Moody, Director, Health 
Promotion, National Department of Health, South Africa; Caleb Otto, Ambassador & Permanent 
Representative of Palau to the United Nations, USA; Dennis Rada, Tobacco Control Coordinator, 
Inter-American Heart Foundation, La Paz, Bolivia; Javier Saimovici, Jefe de la Sección Medicina 
Domiciliaria, Miembro del Programa de Control del Tabaco, Hospital Italiano de Buenos Aires, 
Buenos Aires, Argentina; Oleg Salagay, Deputy Director, Department of International 
Cooperation and Public Relations, Ministry of Health of the Russian Federation, Moscow, Russia; 
Dan Xiao, WHO Collaborating Center for Tobacco or Health, Beijing Institute of Respiratory 
Medicine, Capital Medical University, Beijing, China 
 
 
 
Considering ‘efficacy’ (the effect of an intervention in test conditions compared with a specified 
alternative) in more detail, Cochrane reviews provide rigorous, independent, quantitative estimates 
and are subject to a consistent quality control process. They provide meta-analyses of RCTs usually 
with a minimum of 6 month follow up, synthesising data from direct head-to-head comparisons 
between interventions and comparison conditions.  It is important to recognise that efficacy 
estimates based on the Cochrane reviews depend on the particular circumstances of the trials 
conducted, including the control conditions used and the target population. However, they provide 
the best estimates available and a starting point for consideration of effectiveness. 
 
There are many reasons why efficacy estimates from RCTs might not translate into the same level of 
effectiveness in practice (16), particularly when considering delivery in very different cultures and 
healthcare systems. We believe therefore that it is important to conduct an analysis of likely 
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transferability to different contexts and to supplement efficacy estimates with evidence from ‘real 
world’ studies, which match as closely as possible the context in which the intervention would be 
delivered. Real-world studies often have to be ‘observational’ (involving cohort studies, analysis of 
clinical records or surveys) rather than experimental. This is in part because willingness to be 
randomised to conditions in smoking cessation is a major source of sample bias. By themselves they 
cannot definitely establish a causal connection between interventions and outcomes. However, they 
can help form a judgement about whether or not effect sizes found in RCTs are likely to translate 
into practice in the settings of interest. 
 
An intervention may be effective but not affordable in many countries, particularly low and middle 
income countries. This paper therefore uses the efficacy estimates, qualified if necessary by real-
world effectiveness evidence, to make affordability judgements. Affordability of treatments can be 
construed in a variety of ways (17) depending on whether the individual or the state is paying 
directly, and whether the treatment has to be used over a long period or can be used for a short 
duration.  
 
We define as affordable for a given country, an intervention for which the ICER was less than the 
per capita GDP. This corresponds to the WHO definition of ‘highly cost effective’ (18). It is 
important to recognise that the ICERs for a given country rely on estimates of background quit rates 
and other causes of mortality, as well as effectiveness of interventions if they were to be delivered in 
that country. The background quit rates are mostly not known and so we have to use data from 
countries where they are known and apply appropriate caveats to any conclusions drawn. In 
recognition of all these factors we provide a model (available as a spreadsheet, with instructions, 
accompanying this paper) in which users can vary the parameters used for a given country to assess 
affordability across a range of user-defined assumptions. 
 
An important issue with regard to any tobacco cessation intervention is the question about how far it 
aims to promote attempts to quit versus helping quit attempts to succeed. This leads to what may be 
termed ‘the first law of tobacco cessation’, stated as: 
 
E = N x S 
 
where E is the number of ex-tobacco users generated in a given period, N is the number of tobacco 
users attempting to stop and S is the probability of success of those quit attempts. Note that one may 
adopt different time periods for someone counting as an ex-user, but for present purposes only 
permanent ex-users are considered except for smoking cessation in pregnancy. 
 
While this equation represents an obvious truth, it serves to focus attention on the need to tailor 
intervention strategies to different contexts. For example, in populations where the rate of cessation 
attempts is low but success rates are high, it is more efficient to focus resources on interventions to 
boost N. In populations where N is already high and S is low, it may be more efficient to seek to 
boost S. Of course, N and S may affect each other. For example, availability of more effective 
methods of stopping may boost the rate of attempts to stop. It is necessary to consider these issues 
when considering the different interventions. 
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Related to this is the importance of considering the reach of an intervention. A 1 percentage point 
increase in cessation from intervention A that is delivered to 30% of smokers will have a greater 
population impact than a 5 percentage point increase from intervention B that is only accessed by 
2% of smokers. Thus some of the interventions being reviewed with low effectiveness may have a 
greater impact than others with high effectiveness. 
 
This review covers all forms of tobacco use and is intended to be applicable globally. However, as 
noted earlier, almost all the evidence is from studies of smoking, and from high income countries. 
Where we have been able to find studies from low and middle income countries we have included 
them. In the absence of evidence to the contrary we propose that evidence on smoking cessation 
should be applied to all forms of tobacco cessation, and in the absence of evidence from low and 
middle income countries we propose that the evidence from high income countries be applied to all 
countries, interpreted in the light of national circumstances and priorities. 
 
In summary, this paper provides a concise review of the evidence on tobacco cessation interventions 
for use in guideline development, and in selecting and prioritising cessation interventions at the 
national level, and includes assessments of affordability using an approach based on the one used by 
the WHO. With such a diverse range of interventions and contexts, the conclusions must be stated in 
very broad terms and subject to major caveats. With this in mind the review is accompanied by an 
affordability calculator (Supplementary File) in which users can vary their estimates to assess the 
impact on affordability. 
 
Methods 
 
Efficacy estimation 
 
The Cochrane Library was searched to identify all systematic reviews of the efficacy of healthcare 
tobacco cessation interventions. Healthcare interventions were defined as those that involved 
pharmacological treatment, advice or support from a healthcare worker, printed materials or 
automated systems delivered to individuals or groups. We have included the last two categories of 
intervention because these are important and are often delivered by healthcare agencies. We have 
excluded mass media campaigns although these clearly can promote cessation (19). We have also 
excluded electronic cigarettes and other electronic nicotine delivery systems because of the limited 
amount of available evidence in clinical settings and variability across such products (20). Evidence 
is accumulating rapidly on these and it is likely that we will be able to include them in an update of 
this review in the next couple of years. 
 
Major intervention types were identified from the reviews. Reviews relating to specific subgroups of 
smokers or specific components or forms of behavioural support (e.g., motivational interviewing, 
stage-based interventions, use of incentives) were excluded in order to focus on broad intervention 
categories. Those intervention types with statistically significant overall efficacy relative to a 
comparator from meta-analyses were selected for inclusion in this review. Appendix 1 shows the 
reviews used for primary effect size estimation. Where there was significant variation 
(‘heterogeneity’) in effect sizes from different studies, it was noted. Appendix 2 shows Cochrane 
reviews that were considered and not included or were used to qualify judgements about effect size. 
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The pooled effect sizes from the meta-analyses were recalculated as the overall percentage point 
difference between intervention and comparator conditions together with 95% confidence intervals 
of the estimate, taking account of any heterogeneity in effect size across studies. Studies included in 
the Cochrane reviews typically involved 6-12 months of follow up which allows confident 
extrapolation to permanent cessation in a way that can be used for cost-effectiveness analyses (21). 
Another approach would have been to use the rate ratios (ratios of abstinence rates in intervention 
versus comparison conditions) from the published reviews and apply these to an assumed quit rate in 
the control condition. The results from this approach were very similar to those we obtained except 
in the case of cytisine where applying the rate ratio to a common placebo quit rate resulted in higher 
effective size estimates than we have used. 
 
In the case of some interventions the target population may be all smokers coming into contact with 
a clinical service, whereas in others it may be smokers who are willing to use a particular method to 
help them in a quit attempt. Evidence from high income countries suggests that, even where they are 
widely available, only about 5% of smokers currently use face-to-face behavioural interventions to 
help them stop, but up to 20% use a medication such as nicotine replacement therapy which they can 
buy from a shop or pharmacy (22, 23). 
 
The key efficacy statements in this review take the following form: 
 
• When given to [population category], [intervention category] has been found in multiple (≥2) 
RCTs to increase 6-12 month abstinence rates by [range of values] compared with 
[comparator].  
 
Effectiveness judgements 
 
For internationally applicable statements of effectiveness, it is important to recognise that the 
implementation of the intervention, the intervention provider and population of tobacco users may 
differ widely. For example, evidence on physician advice may or may not generalise to advice from 
other types of healthcare worker, and the effectiveness of a given type of healthcare worker may 
vary across cultures. Therefore it is necessary to form judgements about likely transferability on the 
basis of inference and whatever relevant evidence is available. 
 
A review was conducted using PubMed and Web of Science of studies of effectiveness of the 
interventions covered by the efficacy review. The initial search was conducted using labels to 
identify the intervention (e.g. ‘brief advice’, ‘counselling’, ‘behavioural support’, ‘telephone’, 
‘nicotine replacement therapy’, ‘varenicline’, ‘bupropion’, ‘self-help’, ‘internet’, ‘text messaging’) 
combined with ‘smoking cessation’ or ‘tobacco cessation’. Studies were included if they were RCTs 
that could provide information about the generalisability of the RCTs in the Cochrane reviews, or 
where they were observational studies that estimated the incremental cessation rates in samples 
using the intervention taking account of important confounding variables such as severity of 
dependence on tobacco (24). Judgements about real world effectiveness were made by consensus 
among the authors based on the efficacy findings supplemented by this additional information and 
analysis. The consensus process involved drafting propositions and going through an iterative 
process of redrafting until all the members of the authorship team and international advisory panel 
agreed.  
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Affordability assessments 
 
The starting points for affordability estimates were the efficacy estimates derived from the Cochrane 
reviews, if necessary qualified by effectiveness judgements. These were used to calculate 
incremental cost effectiveness ratios for life years gained (ICERs) based on cost information (see 
below). Because of the high variability in costs in different countries, particularly in the cost of 
healthcare worker time, and potentially different approaches to implementation, only broad estimates 
could be made. However, an affordability calculator is provided in Supplementary File 2 to allow 
users to make estimates using their own data.  
 
Our method of calculating ICERs (25) used life years gained rather than quality-adjusted life years 
as the outcome. This is because there is insufficient information available to assess how far quality 
of life (QoL) may be affected in continuing smokers versus those who stop in different countries, 
and use of quality-adjusted life years is subject to extensive debate (26-28). Stopping smoking 
improves health-related quality of life at all ages as well as life-expectancy and so it would be 
reasonable to expect quality-adjusted life years gained to be at least as high as life years gained (29). 
However, this also depends on how many of the additional life years are spent with poor quality of 
life, and this is subject to too much uncertainty for quality of life to be taken into account in this 
review. 
 
An effective intervention was judged to be ‘affordable’ for a given income category of country if the 
ICER was less than the per capita gross domestic product (GDP) of the reference country in that 
category (Table 2 and Supplementary File). The countries chosen were Nepal, India, China and the 
UK (low, lower middle, upper middle, and high income respectively), ones with good information 
on costs and close to the median per capita GDP for the income category. We considered an 
intervention that would be affordable in all four income categories to be globally affordable. The 
ICER threshold of one per capita GDP corresponds to the WHO definition of ‘highly cost effective’. 
We also used the model to assess affordability in a number of other countries representing all income 
categories and regions (Supplementary File).  
 
We used World Bank data for per capita GDP expressed in international dollars 
(http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD), the WHO table of costs of healthcare 
providers for the different WHO regions for staff costs 
(http://www.who.int/choice/costs/prog_costs/en/index13.html), and expert sources for local costs of 
medications for set-up and ancillary costs. 
 
Medication costs may vary over time, with particular arrangements with manufacturers and to some 
degree in different countries. For our model we took an approximate average price estimate based on 
the information from countries where data were available. Where prices differ, this can be reflected 
in user input to the model. We recommend re-computing affordability estimates when estimates of 
drug costs differ from those assumed here. This can occur when drugs come out of patent and 
generic manufacturers enter the market, or where governments purchase products at discounted 
rates. 
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Where materials and service costs are involved (e.g., automated text messaging), we have used an 
upper estimate and incorporated the set-up costs into a unit cost per quit attempt assuming a 
minimum number of users. Full details of assumptions underlying costs are given in the spreadsheet 
(Supplementary File) notes. Our general principle has been to estimate costs at the upper end of a 
plausible range so that affordability assessments will be conservative. 
 
Note that our affordability assessment takes no account of savings in societal, individual or 
healthcare costs resulting from stopping tobacco use. In many countries these are considerable in the 
case of smoking and mean that many cessation interventions produce a net financial benefit over a 
given timespan. 
 
Results 
 
The efficacy, effectiveness and affordability of the major categories of intervention are presented in 
this section with the behavioural interventions considered first and then the pharmacological 
interventions. Within each of these categories, we consider the interventions in approximate order in 
which effectiveness was first established by Cochrane reviews. Table 1 summarises the main 
conclusions concerning efficacy while Table 2 shows assessments of affordability.  
 
With regard to efficacy statements, some interventions use active comparators as the control 
condition. For example, face-to-face support uses brief advice as a comparator which would in itself 
be expected to have an effect. This means that the total effect of some interventions will be 
underestimated. Therefore, Table 1 also shows a projected estimate of the total effect size of the 
interventions. To be conservative the affordability estimates use the lower figure, but users can enter 
the total effect size estimate in the affordability calculator if they wish.  
 
Some interventions would be expected to combine in terms of effectiveness. For example, 
combining medication to behavioural support is expected to produce an approximately additive 
effect.  
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Table 1: Efficacy of healthcare smoking cessation interventions from Cochrane reviews 
 
Intervention versus 
comparison 
Delivered by Delivered to Percentage 
point increase 
in 6-12 month 
abstinence 
(95% CI)
 
Projected 
percentage 
point increase 
in 6-12 month 
abstinence 
compared with 
no intervention 
Brief advice from a 
physician vs no 
intervention 
Physicians Smokers attending a 
surgery 
2 (2-3) 2 
Printed self-help 
materials versus nothing 
Healthcare 
provider (e.g., 
health promotion 
organisation) 
Smokers wanting help with 
stopping and willing to set 
a quit date 
2 (1-3)
1 
2 
Proactive telephone 
support vs reactive 
telephone support 
Trained stop-
smoking 
practitioners 
Smokers wanting help with 
stopping and willing to set 
a quit date 
3 (2-4)
1,2 
5 
Automated text 
messaging vs non 
smoking-related 
messaging 
Systems 
providers 
Smokers wanting help with 
stopping and willing to set 
a quit date 
4 (3-5)
1 
4 
Face-to-face individual  
behavioural support vs 
brief advice or written 
materials 
Trained stop-
smoking 
practitioners 
Smokers wanting help with 
stopping and willing to set 
a quit date 
4 (3-5)
2 
6 
Face-to-face group-based  
behavioural support vs 
brief advice or written 
materials 
Trained stop-
smoking 
practitioners 
Smokers wanting help with 
stopping and willing to set 
a quit date 
5 (4-7)
2 
7 
Single NRT vs placebo Health 
professionals
3 
Smokers wanting help with 
stopping and willing to set 
a quit date 
6 (6-7)
4 
6 
Dual form/combination 
NRT vs placebo 
Health 
professionals
3
 
Smokers wanting help with 
stopping and willing to set 
a quit date 
11
5 
11 
Cytisine vs placebo Health 
professionals 
Smokers wanting help with 
stopping and willing to set 
a quit date 
6 (4-9)
6 
6 
Bupropion vs placebo Health 
professionals 
Smokers wanting help with 
stopping and willing to set 
a quit date 
7 (6-9)
6 
7 
Nortriptyline vs placebo Health 
professionals 
Smokers wanting help with 
stopping and willing to set 
a quit date 
10 (6-15)
6 
10 
Varenicline vs placebo Health 
professionals 
Smokers wanting help with 
stopping and willing to set 
a quit date 
15 (13-17)
6 
15 
Notes: 
1
Significant heterogeneity, 
2
Use of an active control may mean that the total effect size versus nothing is larger, 
3
Healthcare worker qualified to prescribe or provide the medication, 
4
No clear differences between products or 
interaction with intensity of behavioural support but some evidence that higher dose products are more effective than 
lower dose ones, 
5
Synthetic estimate based on incremental effect of dual form NRT compared with single form, 
6
Studies 
were undertaken in the context of multi-session face-to-face behavioural support. 
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Table 2: Affordability
1
 of healthcare smoking cessation interventions 
 
Intervention
2
  Affordability 
 Low income 
(Nepal) 
Lower middle 
income 
(India) 
Upper middle 
income 
(China) 
High income 
(UK) 
Automated text messaging  7.7 11.2 25.9 109.5 
Brief health worker advice 2.7 7.8 18.0 12.3 
Printed self-help materials  2.4 4.6 10.8 19.3 
Cytisine  1.7 4.9 11.3 15.0 
Nortriptyline  1.4 4.1 9.5 8.6 
Proactive telephone support  1.0 3.8 9.7 4.5 
Face-to-face behavioural support
3
  0.9 3.4 8.6 4.0 
Bupropion 0.5 1.6 3.7 7.7 
Varenicline  0.5 1.3 3.0 9.2 
NRT (single)
4 
0.4 1.0 2.4 6.9 
1
Affordability is the ratio of per capita GDP to the cost per life year gained, i.e. in order for an intervention to be 
affordable, the ‘additional’ cost of saving a life-year must be equal to or less than a country’s per capita GDP (WHO 
criteria for ‘highly cost-effective); e.g. an affordability score of 2 means that the ‘extra’ costs required to save each life 
year is half of a country’s per capita GDP (hence the intervention in question is affordable). 2Affordable interventions are 
marked in bold; 
3
Only individual support is included, 
4
Dual form/combination NRT (transdermal patch plus a faster 
acting form) is more effective than single form but assessing effectiveness and affordability relative to no 
pharmacotherapy would require indirect comparisons and so are not included here. 
 
 
Behavioural interventions 
 
Brief advice 
 
Brief opportunistic advice involves a healthcare worker raising the topic of smoking with a patient, 
advising the patient to stop and/or offering support and follow-up. It would normally be expected to 
take no more than 20 minutes and most of the interventions evaluated took considerably less time 
than this (usually around 5 minutes). 
 
Efficacy: When given by a physician to unselected smokers attending a consultation for a medical 
condition, brief smoking cessation advice has been found in multiple randomised controlled trials to 
increase 6-12 month continuous abstinence rates by an average of 2 percentage points (95% CI=2-3) 
compared with doing nothing or usual care, with an advantage for more intensive compared to 
minimal advice (>20 minutes) (see Table 1) (30). Evidence for efficacy of brief opportunistic advice 
to stop by other healthcare workers is suggestive rather than conclusive (31, 32). 
 
There is insufficient evidence to draw conclusions regarding the efficacy of brief opportunistic 
healthcare worker advice to promote cessation of use of tobacco products other than cigarettes. 
 
Effectiveness: Most of the RCTs thus far have been in high-income countries with healthcare 
systems that have near universal coverage and relates only to physician advice. There is no reason to 
believe that healthcare worker advice would be less effective in low and middle income countries. It 
may be more effective in populations with minimal or no history of quitting because the main effect 
is in prompting quit attempts. A recent RCT involving non-medical healthcare workers delivering 
brief advice on tobacco use cessation door-to-door in slum areas of Delhi found an increase in 6-
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month biochemical verified continuous abstinence rates of 2 percentage points (95%CI 0.2-3) (33). 
Another RCT evaluated a brief motivational intervention delivered by healthcare workers in TBs 
clinics in South Africa and found a doubling of the smoking cessation rates (34). Unfortunately, 
tobacco use is very high in healthcare workers in many countries (35) and this could reduce the 
effectiveness of advice from such workers. The FCTC Article 14 guidelines stress that this issue 
needs addressing with help for healthcare workers to stop (11). 
 
Countries vary considerably in how their healthcare systems are organised, including who would 
deliver brief advice, and how they would be trained and motivated to give brief advice routinely. 
Nevertheless brief advice is potentially usable globally with very wide reach. 
 
Our analysis is that brief advice to stop smoking and offer of support from a healthcare worker can 
have a small but important effect in promoting smoking cessation in any healthcare system that 
invests in the necessary training and support for this activity.  
 
Affordability: With an effect size of 2 percentage points at 6-12 months, brief advice involving an 
average of 20 minutes of health professional time is globally affordable (see Table 2 and 
Supplementary file). Given that many of the studies of brief advice have involved much less than 20 
minutes of advice and that we have based the costs on physician time, the affordability is likely to be 
greater than we have estimated. 
 
Face-to-face behavioural support 
 
Behavioural support involves advice, discussion and encouragement, and other activities designed to 
1) maximise motivation to remain abstinent 2) minimise motivation to smoke 3) enhance the skills 
and capacity needed to avoid and resist urges to smoke and 4) optimise effective use of stop-
smoking medication where available (36, 37). It can be delivered individually or in groups. The 
studies conducted to date have usually involved multiple sessions provided by specially trained 
health professionals over a period from 1 to more than 4 weeks following a target quit date. 
 
Efficacy: When given to smokers who set a quit date and who are willing to receive such help, 
individual face-to-face behavioural support has been found in multiple randomised controlled trials 
to increase 6-12 month continuous abstinence rates by 4 percentage points (95% CI=2-5) compared 
with provision of written materials or brief advice (38). Group support has been found to increase 6-
12 month continuous abstinence rates by 5 percentage points (95% CI=4-7) compared with printed 
self-help materials (39). There is insufficient evidence from RCTs to draw conclusions about 
whether group based support is more effective than individual support (39). Behavioural support has 
been found to add to the efficacy of medication (40). Behavioural support has also been found to be 
effective in helping smokeless tobacco users to quit (3). 
 
Effectiveness: Evidence from the English stop-smoking services, which currently treat 
approximately 700,000 smokers each year, shows success rates lower than would be expected from 
the RCT evidence but greater than would be expected from brief advice. There is considerable 
variability between different local services and individual practitioners (41, 42). This highlights the 
importance of careful staff selection, training and assessment as well as close monitoring of 
outcomes (43).  
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In the English services, group support appears to be more effective than individual support, and 
specialist practitioners (those trained and employed full-time specifically to help tobacco users stop) 
appear to be more effective than those delivering it occasionally in addition to other clinical duties 
(42). 
 
Randomised trials in Pakistan and Malaysia have found behavioural support delivered as part of a 
TB screening and treatment service to have an effect on tobacco cessation (44, 45), strongly 
suggesting that this kind of intervention is practicable and effective in middle income countries when 
integrated into existing care pathways. Several studies in Arabic speaking populations have been 
carried out with mixed results (46). However the quality of the studies is low, limiting the 
conclusions that can be drawn. 
 
Overall, there is reason to believe that face-to-face behavioural support delivered by trained 
healthcare workers with content developed from that used in randomised controlled trials would be 
effective in any healthcare system. There are, however, likely to be significant practical and financial 
barriers to widespread implementation of programmes of this kind in many countries, except where 
they can be incorporated into existing healthcare provision. 
 
Affordability: With an effect size of 4 percentage points at 6-12 months, face-to-face behavioural 
support involving an average of 180 minutes of health worker time per quit attempt would be 
affordable in most middle and high income countries but not in low income countries (Table 2 and 
Supplementary File). 
 
Printed self-help materials  
 
Printed self-help materials include leaflets, booklets and books designed to provide encouragement, 
advice and support to maximise motivation to stop smoking, reduce motivation to smoke, enhance 
self-regulatory skills and capacity and in some cases to optimise medication use.  
 
Efficacy: When given to smokers wanting help with a quit attempt, printed self-help materials have 
been found in multiple randomised trial to increase quit rates by 2 percentage points (95% CI 1-3) 
compared with no intervention  (47). There was significant heterogeneity in the effect sizes.  
 
Effectiveness: It seems reasonable to assume that self-help materials would be effective in a wide 
range of contexts and populations. It is likely that literacy would be a significant factor limiting use 
given that none of the materials evaluated relied exclusively on images. The content and style of the 
materials would be expected to play an important role in effectiveness but there is no evidence to 
indicate what specific components should be included. 
 
Overall, printed self-help materials would be expected to be useful in helping smokers to stop in a 
wide range of settings.  
 
Affordability: If self-help materials could achieve an effect size of 2 percentage points at 6-12 
months, they would be globally affordable (see Table 2 and Supplementary File). If they can be 
distributed electronically via the internet, they become even cheaper (as long as internet access is 
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widespread and inexpensive), as there are no printing and distribution costs. It is also possible in 
some countries that many smokers would buy self-help books or booklets themselves, so that there 
would be no cost to state funders. 
 
Telephone support (quitlines) 
 
Telephone support involves similar broad categories of activity to face-to-face support (see above). 
It can be ‘proactive’ or ‘reactive’.  In proactive support a trained counsellor initiates calls, following 
an initial enquiry by the caller, to provide support according to an agreed schedule, while in a 
reactive model support is available on demand to people who call a quitline number.  
 
Efficacy: When given to smokers wanting help with stopping, proactive telephone support has been 
found in multiple RCTs to increase 6-12 month continuous abstinence rates by 3 percentage points 
(95% CI 2-5) compared with the offer of reactive telephone support only (48). Significant 
heterogeneity exists in the effect sizes of different RCTs, with one large study showing no effect 
(49). This means that we know that telephone support can be effective with the right content, 
delivery and in the right context, but such factors can make a substantial difference. The effect of 
proactive telephone support has been found both for smokers seeking help and those asked if they 
wanted support (50). There is insufficient evidence from RCTs to draw conclusions about the 
efficacy of reactive telephone support. However, as it often includes either or both provision of self-
help materials and/or brief advice from a health professional, it is likely to be similarly effective to 
them. 
 
Effectiveness: A large pragmatic RCT of multilingual proactive telephone support versus self-help 
materials in Asian smokers in California found a clear benefit (51). A recent study in England failed 
to show benefit from adding additional calls and the offer of free NRT to the standard proactive 
service, although NRT is readily available to buy or on prescription in that country and there was 
little differences in usage between intervention control conditions (52).   
 
Our analysis is that there is good reason to believe that proactive telephone support can aid smoking 
cessation in any country although it would be important to monitor success rates to establish that a 
specific service was delivering expected results. 
 
Affordability: With an effect size of 3 percentage points at 6-12 months over reactive support and an 
average of 120 minutes of contact time per quit attempt, telephone support would be globally 
affordable (see Table 2 and Supplementary file).  
 
Automated text messaging 
 
Automated text messaging aims to deliver content similar to face-to-face behavioural support 
focusing on motivational messages, advice on coping with cravings and providing behavioural 
distraction when needed (53). 
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Efficacy: When given to smokers wanting help with stopping, automated text messaging 
interventions have been found in multiple RCTs to increase 6-12 month continuous abstinence rates 
by 4 percentage points (95% CI 3-5) compared with text messaging programmes providing generic 
health advice (54). There is significant heterogeneity in the effect sizes of the studies. 
 
Effectiveness: As long as the content of programmes on offer to smokers is based on what was in the 
successful RCTs, there is reason to believe that broadly similar effects to those found in the RCTs 
would be seen. A large trial of a text messaging intervention, Text2Stop showed a clear benefit (55), 
and an analysis of the content of this intervention has been published (56) which could form a basis 
for development of other programmes. 
 
Our analysis is that automated text messaging programmes can support smokers to stop and the 
content of the programmes should be based on those that have shown a clear benefit. 
 
Affordability: With an effect size of 4 percentage points at 6-12 months automated text messaging is 
globally affordable (see Table 2 and Supplementary file 2), and could  potentially have very good 
reach as some low and middle income countries have high mobile phone ownership. Affordability 
will vary for governments as a function of who bears the phone costs, government or the individual, 
but even if text messaging were entirely government funded it is still likely to be one of the most 
affordable of all interventions. 
Pharmacological interventions 
 
Nicotine Replacement Therapy (NRT)  
 
NRT consists of products designed to deliver nicotine into the body in a form that does not involve 
smoking or ingestion of other toxins. The forms currently licensed for use in at least some countries 
of the world are: 16 hour or 24 hour transdermal patches, 2mg or 4mg chewing gum, 1mg, 1.5mg, 
2mg or 4mg nicotine lozenges, 2mg sublingual tablet, nasal spray, inhalator, buccal pouch and 
mouth spray. Other nicotine products (e.g., some types of electronic nicotine delivery devices) are 
likely to be added to this list of licensed medicines in the coming years. 
 
Smokers typically use these products starting on the designed target quit day and continuing for up 
to 12 weeks. Use can be started before the quit date and they can be used for smoking reduction with 
a view to quitting at a later date. 
 
Efficacy: When given to smokers of 15 or more cigarettes per day who are making a quit attempt on 
a pre-specified day and willing to use NRT, multiple randomised controlled trials have shown that 
this type of aid increases 6-12 month continuous abstinence rates by 6 percentage points (95% CI 6-
7) compared with placebo (57). These studies all involved some degree of contact with a health 
professional. There is no evidence from RCTs that the amount of health professional contact makes a 
difference to the effectiveness of the NRT, although as noted above, behavioural support has been 
shown to have an additive effect in and of itself (40). 
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There is insufficient information to draw conclusions about whether one form of NRT is likely to be 
more effective than another, overall, but evidence suggests that higher dose forms may be more 
effective than lower dose forms (57).  
 
Evidence from multiple randomised controlled trials has shown that combining a nicotine patch with 
a rapid delivery form of NRT (such as gum) increases 6-12 month abstinence rates by 5 percentage 
points compared with single form NRT (95% CI 3-7) (57).  
 
NRT has not been evaluated in smokers of fewer than 10 cigarettes per day and most studies have 
involved smokers of 15 or more cigarettes per day. 
 
There is insufficient evidence from RCTs to draw firm conclusions as to whether or not NRT is an 
effective aid for smokeless tobacco cessation (58). 
 
Effectiveness: Several cross-sectional surveys have been reported as having failed to find that 
smokers using NRT to aid a quit attempt are more likely to still be abstinent at the time of the survey 
(59-61), but the data have in some cases been misinterpreted. Importantly, they failed to adjust 
adequately for major confounding variables such as dependence, and it is known that more 
dependent smokers opt to use NRT (62, 63). A large cross-sectional study and a prospective study 
that adjusted for nicotine dependence found an effect of NRT when prescribed or given by a health 
professional that was similar to that found in RCTs, but no effect when NRT was bought over the 
counter (64, 65). Two other adequately designed prospective studies with sufficient power to detect 
an effect of NRT found that, adjusting for major confounding factors, smokers who used NRT in 
their most recent quit attempt were more likely than those who did not, to maintain abstinence (66, 
67). Both were multinational cohort studies. One involved follow-up for 6 months and the other for a 
year; the effect size in both cases was in line with what would be predicted from the RCTs. It has 
also been shown that smokers in the English stop-smoking services who use NRT are more likely to 
succeed in the short term than those who elect not to use any medication (41). A note of caution is 
sounded by the fact that the only RCT of nicotine patches in a low income country failed to find an 
effect (68). 
 
Overall, our analysis suggests that NRT in the context of at least some behavioural support can aid 
smoking cessation in moderately heavy or heavy smokers. It appears not to be effective when bought 
from shops with no behavioural support. Combining transdermal patches with a faster acting product 
such as chewing gum or lozenge is more effective than using either alone. 
 
Affordability: With an effect size of 6 percentage points at 6-12 months, and assuming up to 40 
minutes of health worker time to explain and supervise use, NRT is affordable in middle and high 
income countries but not in low income countries (see Table 2 and Supplementary file). Generic 
NRT can now be produced cheaply and this will increase its affordability. Prescribing combination 
NRT (patch plus a faster acting form) is likely to be more cost effective because of the additional 
effectiveness of the medication without an increase in prescriber time for supervision (see 
Supplementary File). 
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Bupropion/amfebutamone (sustained release) 
 
Bupropion hydrochloride is an atypical antidepressant that has multiple actions in the brain 
involving dopamine and noradrenaline pathways and may also act as a nicotinic antagonist. A 
typical course is 300mg per day for 7-8 weeks, beginning a week prior to the designated quit date. 
 
Efficacy: When used by smokers of 15 or more cigarettes per day, multiple randomised controlled 
trials have shown that this medication increases 6-12 month continuous abstinence rates by 7 
percentage points (95% CI 6-9) compared with placebo (69). 
 
There is insufficient evidence from RCTs to draw conclusions about whether 300mg (the standard 
dose) is more effective than 150mg (69). 
 
Extending the course of treatment beyond 8 weeks appears to increase abstinence rates while the 
medication is being taken but not when assessed 12 months after the medication has been 
discontinued (69).  
 
Bupropion has not been shown to be effective for treating users of smokeless tobacco (3). 
 
Evidence suggests that bupropion is broadly similar in effectiveness to NRT (69).  
 
Effectiveness: Bupropion has not been tested without behavioural support. Smokers who use it in the 
English stop smoking services have similar short term success rates to those who use single form 
NRT and higher than those who use no medication (41). An RCT undertaken in English clinical 
services found bupropion and the combination of bupropion and NRT to produce similar 6-month 
continuous abstinence rates to single form NRT (70). A prospective multi-national population-level 
study also found that, after adjusting for potential confounding variables, smokers who used 
bupropion in a quit attempt were more likely than those who did not to succeed in stopping (67). A 
note of caution is sounded by the failure of the only RCT of bupropion in a non-high income country 
to show a benefit, although treatment groups were not equivalent and smokers had suspected 
tuberculosis so further trials are needed (44).  
 
Our analysis is that bupropion is a useful aid to smoking cessation in moderately heavy or heavy 
smokers, at least in the context of behavioural support, and is at least as effective as single form 
NRT. 
 
Affordability: With an effect size of 7 percentage points at 6-12 months, bupropion together with 
approximately 60 minutes of health professional time for screening and checking of adverse 
reactions is affordable in middle and high income countries but not in low income countries (see 
Table 2 and Supplementary file). One hour of physician time has been specified for supporting 
medication use because the safety profile and contra-indications of bupropion mean that a prescriber 
would need to spend some time addressing these. 
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Nortriptyline 
 
Nortriptyline is a tricyclic antidepressant. For smoking cessation the dose is typically 75-100mg per 
day for 12-14 weeks, starting 1 week before the quit date.  Because of the side-effect profile, it needs 
close supervision to monitor and possible adjust the dose. 
 
Efficacy: When used by smokers of 15 or more cigarettes per day nortriptyline has been found in 
multiple randomised controlled trials to increase 6-month continuous abstinence rates by 10 (95% CI 
6-15) percentage points compared with placebo (69). Minor adverse events are common, particularly 
dry mouth, but these rarely cause discontinuation of treatment. 
 
Effectiveness: Nortriptyline has not been evaluated without behavioural support. There is a 
reasonable presumption that similar tricyclic antidepressants such as amitriptyline are also effective 
but these have not been tested directly.  
 
A randomised trial among prisoners in Australia did not find a benefit from nortriptyline over and 
above behavioural support (71). An observational study in Brazil found smokers who used 
nortriptyline achieved abstinence rates at least as high as those using bupropion or NRT (72). A 
randomised trial in the UK found no benefit to adding nortriptyline to NRT (73). 
 
Our assessment is that nortriptyline in moderately heavy or heavy smokers in the context of 
behavioural support aids smoking cessation. Patients using it experience some minor adverse 
reactions, particularly dry mouth, but these are not sufficient to undermine effectiveness. 
 
Affordability: Nortriptyline is inexpensive, though the side-effect profile of the drug require more 
extensive supervision. With an effect size of 10 percentage points at 6-12 months, assuming 120 
minutes of prescriber time for supervision, nortriptyline is affordable globally (see Table 2 and 
Supplementary File).  
 
Varenicline 
 
Varenicline is a partial agonist designed to bind with high affinity to the nicotinic acetylcholine 
receptor composed of alpha-4 beta-2 subunits (74). A standard course of treatment is 1mg per day 
beginning 1 week before the designated quit (74), then 11 weeks at 2mg per day. Minor side effects 
reported are nausea and sleep disturbance. These do not appear to lead to significant treatment 
discontinuation. Reports during post-marketing surveillance of raised risk of serious 
neuropsychiatric and cardiac adverse events have not been confirmed by controlled studies (75-78). 
 
Efficacy: When used by smokers of 15 or more cigarettes per day, multiple randomised controlled 
trials have shown that this medication increases 6-12 month continuous or sustained abstinence rates 
by 15 percentage points (95% CI 13-17) compared with placebo and 7 percentage points (95% CI 4-
11) compared with bupropion (74).  
 
Evidence from RCTs suggests that varenicline is more effective than nicotine patches (74). 
 
One trial has shown varenicline to help people stop using smokeless tobacco (3). 
This article is protected by copyright. All rights reserved. 
 
Effectiveness: Varenicline has not been evaluated in RCTs without what would be considered 
intensive behavioural support (multiple sessions with at least 120 minutes of total contact time) but 
an international cohort study strongly suggested effectiveness in routine clinical practice (67). 
Evidence from the English stop-smoking services supports findings from RCTs that varenicline is 
more effective than bupropion or single form NRT (41).   
 
Our assessment is that varenicline in moderately heavy or heavy smokers in the context of 
behavioural support aids smoking cessation. On average it is more effective than bupropion and 
single form NRT and at least as effective as combination NRT. Although there is little reason at 
present to believe that it can cause serious side effects, concerns have been raised and it has been 
suggested that healthcare workers show particular vigilance in case these emerge. 
 
Affordability: With an effect size of 15 percentage points at 6-12 months, varenicline together with 
approximately 60 minutes of health professional time is affordable in middle and high income 
countries but not in low income countries (see Table 2 and Supplementary File). 
 
Cytisine 
 
Cytisine is a partial agonist binding with high affinity to the nicotinic acetylcholine receptor 
composed of alpha-4 beta-2 subunits (74). A standard course of treatment is 4 weeks, beginning 1 
week before the designated quit date, with dosing regimen that reduces over time. It was the first 
medication ever to be licensed as a smoking cessation aid and has been in use in Eastern Europe for 
more than 40 years. In Russia and Poland it is available for purchase over the counter. No serious 
side effects have been detected. Nausea is a common minor side effect but does not lead to 
significant discontinuation of treatment. 
 
Efficacy: When used by smokers of 15 or more cigarettes per day, cytisine has been found in 
multiple RCTs to increase 6-12 month continuous abstinence rates by 6 percentage points (95% CI 
4-9) compared with placebo (74).  
 
Effectiveness: An observational study from a large clinic in Warsaw found 12-month biochemically 
verified abstinence rates somewhat greater than was found in a large clinical trial in the same clinic 
(79, 80). This suggests that the results of the RCTs would translate into routine clinical practice. 
 
An open-label RCT in smokers calling the New Zealand telephone helpline found cytisine to be 
more effective than nicotine replacement therapy (81). 
 
There are more than 4 million users on the European Medicines Agency drug safety database and no 
evidence has emerged of any safety problems, suggesting that this drug has a benign safety profile 
and is suitable for purchase with minimal or no medical supervision, as is currently the case in 
Russia and Poland. 
 
Our assessment is that cytisine is an effective aid to cessation in moderately heavy to heavy smokers. 
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Affordability: With an effect size of 6 percentage points at 6-12 months, and requiring relatively 
little clinical supervision (approximately 40 minutes), cytisine would be globally affordable (see 
Table 2 and Supplementary File). 
 
Table 3: Narrative summary of main conclusions  
 
Intervention Effectiveness Affordability 
Brief opportunistic 
advice from a healthcare 
worker 
This is an effective means of promoting tobacco 
cessation. The main issue is likely to be motivating and 
training health workers to deliver this intervention 
routinely as well as ensuring the healthcare worker is not 
a tobacco user. It may be that offering help with stopping 
to all tobacco users provides optimum results. 
Globally affordable 
Printed self-help 
materials 
This is an effective means of promoting tobacco 
cessation. It will be important to match intervention 
content as closely as possible to what has been found to 
be effective. 
Globally affordable 
Proactive telephone 
support 
This is an effective means of promoting tobacco 
cessation. Effectiveness will depend on having in place 
appropriate procedures for selection, training, assessment 
and professional development of practitioners as well as 
evidence-based treatment protocols. 
Globally affordable 
Automated text 
messaging 
This is an effective means of promoting tobacco 
cessation. It will be important to match intervention 
content as closely as possible to what has been found to 
be effective. 
Globally affordable 
Face-to-face behavioural 
support 
This is an effective means of promoting tobacco 
cessation. In many countries it may need to be integrated 
into existing services (e.g. TB screening). Effectiveness 
will depend on having in place appropriate procedures 
for selection, training, assessment and professional 
development of practitioners as well as evidence-based 
treatment protocols. Its effect appears to be broadly 
additive to medication if that is being used. 
Affordable in 
middle and high 
income countries 
Nicotine replacement 
therapy 
This is an effective intervention when provided by a 
healthcare worker. Best results can be achieved by 
combining a transdermal patch with a faster acting form.  
Affordable in 
middle and high 
income countries 
Cytisine This is an effective intervention when provided by a 
healthcare worker. 
Globally affordable 
Bupropion This is an effective intervention when provided by a 
healthcare worker. It is affordable in middle and high 
income countries but not in low income countries. It is 
broadly similar in effectiveness to single form NRT. 
Affordable in 
middle and high 
income countries 
Nortriptyline This is an effective and globally affordable intervention 
when provided by a healthcare worker. 
Globally affordable 
Varenicline This is an effective intervention when provided by a 
healthcare worker. It is more effective than bupropion 
and single form NRT.  
Affordable in 
middle and high 
income countries 
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Discussion 
 
Table 3 gives a narrative summary of the judged effectiveness and affordability of the interventions 
reviewed. All are judged to be affordable in middle and high income countries and many are 
affordable in low income countries.  
 
The most effective combination of interventions on the basis of our review is face-to-face 
behavioural support together with combination NRT or varenicline. However this combination is 
currently only likely to be affordable in middle and high income countries (although, of course, users 
who can afford it may choose to pay for it). 
 
A major outcome of this review is that, based on reasonable assumptions about cost, and not taking 
any account of cost savings from tobacco cessation, healthcare systems of countries in every World 
Bank income category should be able to afford to implement smoking cessation interventions of 
established efficacy. Most notably, these are brief advice from a healthcare worker, proactive 
telephone support, printed self-help materials, text messaging support, and provision of medication 
such as cytisine or nortriptyline. Clearly there are major practical challenges to achieving this and 
countries not currently doing this will need to give careful consideration to the pace of development 
that can be achieved, and which interventions to prioritise. Nevertheless, this review and our 
affordability calculator offer a basis for countries to establish what level of cessation provision they 
might aim for. 
 
It is important to note that the affordability judgements are very broad and do not take into account 
important factors that may be operating in particular countries. For example, in countries such as 
Brazil and India, income is highly skewed and there are large numbers of very poor people in rural 
communities with limited access to healthcare. Furthermore, in many countries healthcare is 
provided principally by healthcare workers who are not medically or professionally trained, and in 
others by traditional health practitioners. This may necessitate considerable adaptation of training in, 
for example, brief advice, to local culture, infrastructure and traditions. A recent international survey 
of treatment provision found broad agreement with our findings of the affordability of medications 
globally (13). 
 
This review has identified many important gaps in the tobacco cessation literature. There is little 
evidence about interventions relating to tobacco use other than cigarette smoking. More evidence is 
needed on how to deliver effective behavioural support, both in terms of the development of 
treatment manuals and delivery by individual practitioners. It is also important to identify factors 
that influence medication effectiveness in real-world settings, including adherence to the treatment 
regimen, to assess the potential for internet-based interventions, and how to make interventions more 
attractive to tobacco users. There are now more than 250 smartphone applications that claim to aid 
smoking cessation, but these have not yet been evaluated adequately (83). Research is also needed to 
investigate how to implement brief advice in primary and secondary healthcare in high, as well as 
middle and low, income countries. Research is needed into the potential for electronic nicotine 
delivery systems and in methods to improve the reach and/or effectiveness of nicotine replacement 
therapies. A key priority is how best to motivate and support practitioners, and adapt healthcare 
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delivery systems to integrate brief advice into healthcare systems, as recommended by the FCTC 
Article 14 guidelines.  
 
There is a significant gap in the literature on the effectiveness of combining different interventions. 
We have used an additive model for the combination of behavioural support and medication but it is 
not clear whether this is correct. It could have been anything from multiplicative to partially 
additive. This is an important area for future research. 
 
Our current understanding of affordability of tobacco cessation interventions could benefit hugely 
from more advanced future economic modelling when better data become available. Until such a 
time, we believe that our practical, customisable spreadsheet will provide local decision makers with 
a practical, evidence based tool to help select effective, affordable tobacco cessation interventions 
for their country.  
 
This review has not considered tobacco harm reduction, defined as ‘measures taken to reduce the 
harm from continued use of tobacco or tobacco-derived products’. This typically involves users 
reducing consumption of cigarettes or switching to less harmful products. For example, the 
smokeless tobacco, snus, may provide a means of stopping smoking.  
 
A crucial issue with regard to effectiveness, affordability and reach concerns the logistics of 
delivering interventions and the effects of the setting on these parameters. This will vary 
considerably across countries and regions and it is likely that considerable local expertise will be 
required to establish how interventions can be integrated with existing services. 
 
This review has been produced to support country-specific national guideline development for 
smoking cessation, by serving as a review of the evidence base, thus removing the need for a country 
to re-review the evidence, a process that can be costly and time consuming, and to provide a starting 
point for considering what resources to devote to tobacco cessation support, and what the optimum 
blend of interventions might be. We hope it will be used alongside a detailed analysis at country 
level, by all relevant stakeholders working together, to determine cessation priorities within a 
country. 
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Appendix 1: Cochrane Reviews healthcare smoking cessation interventions included in this 
review 
 
Cochrane Review Effective intervention 
Cahill K, Stead LF, Lancaster T. Nicotine receptor partial 
agonists for smoking cessation. The Cochrane database of 
systematic reviews. 2012;4:CD006103. 
Varenicline 
Cytisine 
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological 
interventions for smoking cessation: an overview and network 
meta-analysis. The Cochrane database of systematic reviews. 
2013;5:CD009329. 
Nicotine Replacement Therapy 
Bupropion 
Varenicline 
Nortriptyline 
Cytisine 
Civljak M, Stead LF, Hartmann-Boyce J, Sheikh A, Car J. 
Internet-based interventions for smoking cessation. The 
Cochrane database of systematic reviews. 2013;7:CD007078. 
Internet-based support 
Hartmann-Boyce J, Lancaster T, Stead LF. Print-based self-help 
interventions for smoking cessation. The Cochrane database of 
systematic reviews. 2014;6:CD001118. 
Printed self-help materials 
Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. 
Antidepressants for smoking cessation. The Cochrane database 
of systematic reviews. 2014;1:CD000031. 
Bupropion 
Nortriptyline 
Lancaster T, Stead LF. Individual behavioural counselling for 
smoking cessation. The Cochrane database of systematic 
reviews. 2005(2):CD001292. 
Face-to-face behavioural 
support 
Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce 
J, Lancaster T. Physician advice for smoking cessation. The 
Cochrane database of systematic reviews. 2013;5:CD000165. 
Brief advice 
Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone 
counselling for smoking cessation. The Cochrane database of 
systematic reviews. 2013;8:CD002850. 
Telephone-based behavioural 
support 
Stead LF, Lancaster T. Behavioural interventions as adjuncts to 
pharmacotherapy for smoking cessation. The Cochrane database 
of systematic reviews. 2012;12:CD009670. 
Face-to-face behavioural 
support 
Stead LF, Lancaster T. Combined pharmacotherapy and 
behavioural interventions for smoking cessation. The Cochrane 
database of systematic reviews. 2012;10:CD008286. 
Face-to-face behavioural 
support 
Stead LF, Lancaster T. Group behaviour therapy programmes for 
smoking cessation. The Cochrane database of systematic 
reviews. 2005(2):CD001007. 
Face-to-face behavioural 
support 
Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, 
Cahill K, et al. Nicotine replacement therapy for smoking 
cessation. The Cochrane database of systematic reviews. 
2012;11:CD000146. 
Nicotine replacement therapy 
Whittaker R, McRobbie H, Bullen C, Borland R, Rodgers A, Gu 
Y. Mobile phone-based interventions for smoking cessation. The 
Cochrane database of systematic reviews. 2012;11:CD006611. 
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Appendix 2: Cochrane reviews not included in primary effect size calculation and reasons
1 
 
Bala MM, Strzeszynski L, Topor-Madry R, Cahill K. 
Mass media interventions for smoking cessation in 
adults. The Cochrane database of systematic reviews. 
2013;6:CD004704. 
Not a healthcare intervention 
Barnes J, Dong CY, McRobbie H, Walker N, Mehta M, 
Stead LF. Hypnotherapy for smoking cessation. The 
Cochrane database of systematic reviews. 
2010(10):CD001008. 
Specific component of 
support 
Barth J, Critchley J, Bengel J. Psychosocial 
interventions for smoking cessation in patients with 
coronary heart disease. The Cochrane database of 
systematic reviews. 2008(1):CD006886. 
Specific population 
Baxi R, Sharma M, Roseby R, Polnay A, Priest N, 
Waters E, et al. Family and carer smoking control 
programmes for reducing children's exposure to 
environmental tobacco smoke. The Cochrane database 
of systematic reviews. 2014;3:CD001746. 
Specific component of 
support 
Bize R, Burnand B, Mueller Y, Rege-Walther M, 
Camain JY, Cornuz J. Biomedical risk assessment as an 
aid for smoking cessation. The Cochrane database of 
systematic reviews. 2012;12:CD004705. 
Specific component of 
support 
Boyle R, Solberg L, Fiore M. Use of electronic health 
records to support smoking cessation. The Cochrane 
database of systematic reviews. 2011(12):CD008743. 
Infrastructure rather than 
direct intervention 
Brinn MP, Carson KV, Esterman AJ, Chang AB, Smith 
BJ. Mass media interventions for preventing smoking in 
young people. The Cochrane database of systematic 
reviews. 2010(11):CD001006. 
Not a healthcare intervention 
Cahill K, Lancaster T, Green N. Stage-based 
interventions for smoking cessation. The Cochrane 
database of systematic reviews. 2010(11):CD004492. 
Specific component of 
support 
Cahill K, Lancaster T. Workplace interventions for 
smoking cessation. The Cochrane database of 
systematic reviews. 2014;2:CD003440. 
Specific setting 
Cahill K, Perera R. Competitions and incentives for 
smoking cessation. The Cochrane database of 
systematic reviews. 2011(4):CD004307. 
Not a healthcare intervention 
Cahill K, Ussher MH. Cannabinoid type 1 receptor 
antagonists for smoking cessation. The Cochrane 
database of systematic reviews. 2011(3):CD005353. 
Not clearly effective
2 
Callinan JE, Clarke A, Doherty K, Kelleher C. 
Legislative smoking bans for reducing secondhand 
smoke exposure, smoking prevalence and tobacco 
consumption. The Cochrane database of systematic 
Not a healthcare intervention 
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reviews. 2010(4):CD005992. 
Carson KV, Brinn MP, Labiszewski NA, Esterman AJ, 
Chang AB, Smith BJ. Community interventions for 
preventing smoking in young people. The Cochrane 
database of systematic reviews. 2011(7):CD001291. 
Not a healthcare intervention 
Carson KV, Brinn MP, Peters M, Veale A, Esterman 
AJ, Smith BJ. Interventions for smoking cessation in 
Indigenous populations. The Cochrane database of 
systematic reviews. 2012;1:CD009046. 
Specific population 
Carson KV, Verbiest ME, Crone MR, Brinn MP, 
Esterman AJ, Assendelft WJ, et al. Training health 
professionals in smoking cessation. The Cochrane 
database of systematic reviews. 2012;5:CD000214. 
Infrastructure rather than 
direct intervention 
Chamberlain C, O'Mara-Eves A, Oliver S, Caird JR, 
Perlen SM, Eades SJ, et al. Psychosocial interventions 
for supporting women to stop smoking in pregnancy. 
The Cochrane database of systematic reviews. 
2013;10:CD001055. 
Specific population 
Coleman T, Chamberlain C, Davey MA, Cooper SE, 
Leonardi-Bee J. Pharmacological interventions for 
promoting smoking cessation during pregnancy. The 
Cochrane database of systematic reviews. 
2012;9:CD010078. 
Specific population 
Coppo A, Galanti MR, Giordano L, Buscemi D, 
Bremberg S, Faggiano F. School policies for preventing 
smoking among young people. The Cochrane database 
of systematic reviews. 2014;10:CD009990. 
Not a healthcare intervention 
Critchley J, Capewell S. Smoking cessation for the 
secondary prevention of coronary heart disease. The 
Cochrane database of systematic reviews. 
2004(1):CD003041. 
Specific population 
Critchley JA, Capewell S. WITHDRAWN: Smoking 
cessation for the secondary prevention of coronary heart 
disease. The Cochrane database of systematic reviews. 
2012;2:CD003041. 
Specific population 
David SP, Lancaster T, Stead LF, Evins AE, Prochaska 
JJ. Opioid antagonists for smoking cessation. The 
Cochrane database of systematic reviews. 
2013;6:CD003086. 
Not clearly effective
2 
Gourlay SG, Stead LF, Benowitz NL. Clonidine for 
smoking cessation. The Cochrane database of 
systematic reviews. 2004(3):CD000058. 
Not feasible because of side 
effects 
Hajek P, Stead LF, West R, Jarvis M, Hartmann-Boyce 
J, Lancaster T. Relapse prevention interventions for 
smoking cessation. The Cochrane database of 
systematic reviews. 2013;8:CD003999. 
Specific component of 
support 
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Hajek P, Stead LF. Aversive smoking for smoking 
cessation. The Cochrane database of systematic 
reviews. 2004(3):CD000546. 
Specific component of 
support 
Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. 
Nicotine vaccines for smoking cessation. The Cochrane 
database of systematic reviews. 2012;8:CD007072. 
Not clearly effective
2 
Hughes JR, Stead LF, Lancaster T. Anxiolytics for 
smoking cessation. The Cochrane database of 
systematic reviews. 2000(4):CD002849. 
Not clearly effective
2 
Johnston V, Liberato S, Thomas D. Incentives for 
preventing smoking in children and adolescents. The 
Cochrane database of systematic reviews. 
2012;10:CD008645. 
Not a healthcare intervention 
Lai DT, Cahill K, Qin Y, Tang JL. Motivational 
interviewing for smoking cessation. The Cochrane 
database of systematic reviews. 2010(1):CD006936. 
Specific component of 
support 
Lancaster T, Stead LF. Mecamylamine (a nicotine 
antagonist) for smoking cessation. The Cochrane 
database of systematic reviews. 2000(2):CD001009. 
Not clearly effective
2 
Lancaster T, Stead LF. Silver acetate for smoking 
cessation. The Cochrane database of systematic 
reviews. 2012;9:CD000191. 
Not clearly effective
2 
Lovato C, Watts A, Stead LF. Impact of tobacco 
advertising and promotion on increasing adolescent 
smoking behaviours. The Cochrane database of 
systematic reviews. 2011(10):CD003439. 
Not a healthcare intervention 
Lumley J, Chamberlain C, Dowswell T, Oliver S, 
Oakley L, Watson L. Interventions for promoting 
smoking cessation during pregnancy. The Cochrane 
database of systematic reviews. 2009(3):CD001055. 
Specific population 
Maziak W, Ward KD, Eissenberg T. Interventions for 
waterpipe smoking cessation. The Cochrane database of 
systematic reviews. 2007(4):CD005549. 
Not clearly effective
2 
Park EW, Tudiver FG, Campbell T. Enhancing partner 
support to improve smoking cessation. The Cochrane 
database of systematic reviews. 2012;7:CD002928. 
Specific component of 
support 
Rice VH, Hartmann-Boyce J, Stead LF. Nursing 
interventions for smoking cessation. The Cochrane 
database of systematic reviews. 2013;8:CD001188. 
Specific health professional 
group 
Rigotti NA, Clair C, Munafo MR, Stead LF. 
Interventions for smoking cessation in hospitalised 
patients. The Cochrane database of systematic reviews. 
2012;5:CD001837. 
Specific population 
Sinclair HK, Bond CM, Stead LF. Community 
pharmacy personnel interventions for smoking 
cessation. The Cochrane database of systematic 
Specific health professional 
group 
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reviews. 2004(1):CD003698. 
Stead LF, Hughes JR. Lobeline for smoking cessation. 
The Cochrane database of systematic reviews. 
2012;2:CD000124. 
Not clearly effective
2 
Stead LF, Lancaster T. Nicobrevin for smoking 
cessation. The Cochrane database of systematic 
reviews. 2006(2):CD005990. 
Not clearly effective
2 
Thomas RE, McLellan J, Perera R. School-based 
programmes for preventing smoking. The Cochrane 
database of systematic reviews. 2013;4:CD001293. 
Not a healthcare intervention 
Thomsen T, Villebro N, Moller AM. Interventions for 
preoperative smoking cessation. The Cochrane database 
of systematic reviews. 2014;3:CD002294. 
Specific population 
Tsoi DT, Porwal M, Webster AC. Interventions for 
smoking cessation and reduction in individuals with 
schizophrenia. The Cochrane database of systematic 
reviews. 2013;2:CD007253. 
Specific population 
Ussher MH, Taylor AH, Faulkner GE. Exercise 
interventions for smoking cessation. The Cochrane 
database of systematic reviews. 2014;8:CD002295. 
Specific component of 
support 
van der Meer RM, Wagena EJ, Ostelo RW, Jacobs JE, 
van Schayck CP. Smoking cessation for chronic 
obstructive pulmonary disease. The Cochrane database 
of systematic reviews. 2003(2):CD002999. 
Specific population 
van der Meer RM, Willemsen MC, Smit F, Cuijpers P. 
Smoking cessation interventions for smokers with 
current or past depression. The Cochrane database of 
systematic reviews. 2013;8:CD006102. 
Specific population 
White AR, Rampes H, Liu JP, Stead LF, Campbell J. 
Acupuncture and related interventions for smoking 
cessation. The Cochrane database of systematic 
reviews. 2014;1:CD000009. 
Not clearly effective
2 
1
Some of these reviews are referred to in the paper to qualify statements about effect size estimates 
2
These are categories of intervention not found to be effective rather than reviews of included 
interventions where the review failed to show an effect 
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